Clinical trial

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients…

NCT00296374 · AstraZeneca, Industry · Completed

Key facts

NCT number NCT00296374
Title Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
Official title Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria
Acronym PLANET 1
Lead sponsor AstraZeneca, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Diabetes Mellitus
Intervention type Drug
Interventions Rosuvastatin, Atorvastatin
Enrollment 353
Start date Feb 1, 2006
Primary completion Mar 1, 2009
Completion Mar 1, 2009
First posted Feb 27, 2006
Last update posted Sep 1, 2011
Countries Argentina, Brazil, Bulgaria, Canada, Denmark, France, Hungary, Italy, Mexico, Romania, United States

At a glance

  • 100–999 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies